Rapid Micro Biosystems, Inc. (RPID) — SEC Filings
Rapid Micro Biosystems, Inc. (RPID) — 23 SEC filings. Latest: 10-Q (Nov 7, 2025). Includes 12 8-K, 6 10-Q, 2 DEF 14A.
View Rapid Micro Biosystems, Inc. on SEC EDGAR
Overview
Rapid Micro Biosystems, Inc. (RPID) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 7, 2025: RAPID MICRO BIOSYSTEMS, INC. (RPID) reported a net loss of $11.505 million for the three months ended September 30, 2025, a slight increase from the $11.323 million net loss in the prior-year period. For the nine months ended September 30, 2025, the net loss was $34.626 million, an improvement from
Sentiment Summary
Across 23 filings, the sentiment breakdown is: 3 bearish, 19 neutral, 1 mixed. The dominant filing sentiment for Rapid Micro Biosystems, Inc. is neutral.
Filing Type Overview
Rapid Micro Biosystems, Inc. (RPID) has filed 6 10-Q, 12 8-K, 2 DEF 14A, 1 10-K, 2 SC 13G/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (23)
Risk Profile
Risk Assessment: Of RPID's 19 recent filings, 3 were flagged as high-risk, 7 as medium-risk, and 9 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $7,838,000 |
| Net Income | -$11,505,000 |
| EPS | -$0.26 |
| Debt-to-Equity | 0.90 |
| Cash Position | $18,946,000 |
| Operating Margin | -145.07% |
| Total Assets | $84,407,000 |
| Total Debt | $22,230,000 |
Key Executives
- Dr. Robert J. Brown
- Robert L. Johnson
Industry Context
The rapid diagnostics market, particularly for microbial detection, is highly competitive and driven by technological innovation and regulatory approvals. Companies like RPID face pressure to demonstrate the efficacy and cost-effectiveness of their solutions against established methods and emerging competitors. Trends include the increasing demand for faster, more accurate diagnostic tools in healthcare and industrial settings, as well as the growing importance of automation and data analytics in laboratory workflows.
Top Tags
10-Q (4) · corporate-governance (3) · financials (3) · reporting (3) · Biotechnology (2) · Revenue Decline (2) · SEC Filing (2) · financial-statements (2) · exhibits (2) · sec-filing (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $11.505M | Slightly higher than $11.323M in Q3 2024, indicating continued unprofitability. |
| Net Loss (YTD 2025) | $34.626M | Improved from $37.223M in YTD 2024, showing some progress in loss reduction. |
| Total Revenue (Q3 2025) | $7.838M | Increased from $7.604M in Q3 2024, driven by service revenue growth. |
| Service Revenue (Q3 2025) | $2.624M | Up 11.7% from $2.349M in Q3 2024, a positive growth driver. |
| Product Revenue (Q3 2025) | $5.214M | Down 0.78% from $5.255M in Q3 2024, indicating stagnation in product sales. |
| Total Operating Expenses (Q3 2025) | $19.210M | Decreased 2.2% from $19.643M in Q3 2024, reflecting cost management efforts. |
| Cash and Cash Equivalents (Sept 30, 2025) | $18.946M | Increased from $16.911M at Dec 31, 2024, providing some liquidity. |
| Notes Payable, Net (Sept 30, 2025) | $18.828M | New debt incurred, significantly increasing total liabilities from $22.817M to $40.075M. |
| Accumulated Deficit (Sept 30, 2025) | $509.900M | Highlights the company's history of significant losses and ongoing challenge to achieve profitability. |
| Weighted Average Common Shares Outstanding (Q3 2025) | 44,956,131 | Increased from 43,668,656 in Q3 2024, indicating potential dilution. |
| Total Revenue (Q2 2025) | $6.0M | Decreased from $6.4M in Q2 2024, indicating a 6.25% decline. |
| Product Revenue (Q2 2025) | $3.5M | Fell from $4.0M in Q2 2024, highlighting a core business challenge. |
| Service Revenue (Q2 2025) | $2.5M | Remained stable compared to $2.4M in Q2 2024, providing some stability. |
| Total Revenue (YTD June 2025) | $12.0M | Down from $12.5M in the prior year, showing a consistent downward trend. |
| Q2 Revenue Decline | 6.25% | Percentage decrease in total revenue from Q2 2024 to Q2 2025. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Rapid Micro Biosystems, Inc. (RPID)?
Rapid Micro Biosystems, Inc. has 23 recent SEC filings from Jan 2024 to Nov 2025, including 12 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RPID filings?
Across 23 filings, the sentiment breakdown is: 3 bearish, 19 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Rapid Micro Biosystems, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Rapid Micro Biosystems, Inc. (RPID) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Rapid Micro Biosystems, Inc.?
Key financial highlights from Rapid Micro Biosystems, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for RPID?
The investment thesis for RPID includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Rapid Micro Biosystems, Inc.?
Key executives identified across Rapid Micro Biosystems, Inc.'s filings include Dr. Robert J. Brown, Robert L. Johnson.
What are the main risk factors for Rapid Micro Biosystems, Inc. stock?
Of RPID's 19 assessed filings, 3 were flagged high-risk, 7 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Rapid Micro Biosystems, Inc.?
Forward guidance and predictions for Rapid Micro Biosystems, Inc. are extracted from SEC filings as they are enriched.